AMPEL BioSolutions employs a multipronged approach to discover new drugs.
WHAT WE DO
AMPEL BioSolutions is transformative in determining a candidate drugs’ potential as a novel disease intervention by tailoring novel therapies to apply to the right patient at the right time with the right indication. This approach involves candidate drug profiling, clinical trial design and management as well as identification of new molecular pathways for potential targeting.
Not only does AMPEL excel at an all-encompassing data analysis approach to provide the most accurate results, it quickly executes. From conception to execution, AMPEL is able to launch research ideas and mandates efficiently and effectively.
AMPEL uses state of the art techniques to analyze clinical and research data from the literature and large databases. Expertise includes flow cytometry, gene expression (microarray and RNAseq), and bioinformatics.
AMPEL BioSolutions is the leading biomedical research think tank that creatively overcomes clinical development bottlenecks and R&D roadblocks. AMPEL can assemble, analyze, interpret & synthesize biomedical information to provide solutions to the most pressing research needs.
Determining the most effective molecular biomarkers for evaluating pharmacodynamic activity and drug efficacy as well as the linkage between the two is an essential part of informative and successful clinical trials. Using Biologic, Molecular, Genetic and Bioinformatic approaches, AMPEL is at the forefront of identifying the newest and most accurate biomarkers.
- Innate and Adaptive Immunity
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Rheumatoid Arthritis
- Rheumatic Autoimmune/Inflammatory
- Drug Repositioning
- Clinical Design and Management
- Biomarker Discovery